Confronting atrial fibrillation in the elderly: Stroke risk stratification and emerging antithrombotic therapies

Geriatrics

Volumn 62, Issue 3, 2007, Pages 22-27

  Strong, Samantha H ^a   Halperin, Jonathan L ^b  

^a KAISER PERMANENTE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Risk stratification; Stroke; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; WARFARIN;

AGE; AGED; AGING; BRAIN HEMORRHAGE; DIABETES MELLITUS; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEUKOARAIOSIS; NEUROIMAGING; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; VASCULAR AMYLOIDOSIS;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; GERIATRICS; HUMANS; HYPERTENSION; MALE; RISK ASSESSMENT; WARFARIN;

EID: 33947409149     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Miyakasa Y, Barnes ME, Gersh BJ, et al. Circulation 2006; 114:119-25.
2. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27:949-53.
3. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004; 110(9):1042-46.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987; 147:1561-4.
5. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998; 97:1231-3.
6. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-26.
7. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-34.
8. Brass LM, Krumholz HM, Scinto JD, et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med 1998; 158:2093-100.
9. Aronow WS, Ahn C, Kronzon I, et al. Incidence of new thromboembolic stroke in persons 62 years and older with chronic atrial fibrillation treated with warfarin versus aspirin. J Am Geriatr Soc 1999; 47:366-8.
10. Nieuwlaat R, Capucci A, Lip GY, et al. Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006 (E-published).
11. EAFT (European Atrial Fibrillation Trial) Study Group. European Atrial Fibrillation Trial: Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993; 342:1255-62.
12. Jorgensen HS Nakayama H, Reith J, Raasschou HO, Olsen TS. Stroke recurrence: predictors, severity and prognosis: The Copenhagen Stroke Study. Neurology 1997; 48:891-5.
13. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160:41-6.
14. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Long-term antithrombotic therapy for chronic atrial fibrillation or atrial flutter: Anticoagulants and antiplatelet agents. In Seventh ACCP consensus conference on antithrombotic therapy: Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians. Chest (Suppl) 2004; 126:429S-56S.
15. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention In Atrial Fibrillation Study: final results. Circulation 1991; 84:527-39.
16. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996; 348:633-8.
17. ACTIVE Writing Group on behalf of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet 2006; 367:1877-8.
18. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA 2001; 285:2864-70.
19. Hart RG, Tonarelli SB, Pearce LA. Avoiding ventral nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36:1588-93.
20. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006; 354:934-41.
21. Pappone C. Ablation for paroxysmal atrial fibrillation trial. Preliminary results released at the annual meeting of the ACC.
22. Healy JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol 2005; 45:1832-9.